A trial of pembrolizumab before surgery for bowel cancer (NEOPRISM-CRC)
Cancer type:
Status:
Phase:
This trial is looking to see if having pembrolizumab before surgery improves treatment for bowel cancer that has a high risk of coming back.
It is for people who:
- are going to have surgery to remove their cancer and
- have certain gene changes (
mutations ) in their cancer cells
More about this trial
Most people have surgery for bowel cancer that hasn’t spread. You might also have chemotherapy after surgery.
Doctors are looking for ways to improve treatment for people whose bowel cancer hasn’t spread. In this trial they are looking at having a drug called pembrolizumab before surgery. Pembrolizumab is a type of immunotherapy. It stimulates the body's
The main aims of the trial are to find out:
- how safe it is to have pembrolizumab before surgery
- how well pembrolizumab works
- more about the side effects of treatment
Who can enter
The following bullet points are a summary of the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if all of the following apply. You:
- have
adenocarcinoma of the bowel. This includes rectal cancer if you won’t need to havechemoradiotherapy before surgery. - have cancer that may have spread to nearby
lymph nodes or to surrounding tissue. But it hasn’t spread to distant parts of the body. This is stage 2 to stage 3 cancer. - have cancer that is microsatellite instability high (
MSI high ) or mismatch repair deficient (MMRd) . Your doctor will know this. - are well enough to have surgery with the aim to cure followed by chemotherapy
- have satisfactory blood test results
- are willing to use reliable contraception during the trial and for a period after if there is any chance you or your partner could become pregnant
- are at least 18 years old
Who can’t take part
Cancer related
You cannot join this trial if any of these apply. You:
- have cancer spread to the brain or spinal cord
- have cancer that has spread elsewhere in the body or into the lymph nodes around the abdomen (
peritoneum ) - are going to have radiotherapy
- have had pembrolizumab in the past or a similar drug
- have had another cancer drug in the 4 weeks before you join the trial
- have moderate to severe side effects from past treatment that aren’t getting better. You can join if you have hair loss or numbness and tingling in your hands or feet (
peripheral neuropathy ). - have or had another cancer that could affect the assessments doctors do to check if treatment is working
- are taking an experimental drug or using a device as part of another clinical trial. This is if it is within 28 days of joining this trial.
Medical conditions
You cannot join this trial if any of these apply. You:
- have a problem with how your kidneys and liver work
- have had a severe skin reaction to other drugs that stimulate the immune system
- have an
autoimmune condition that needs treatment apart from certain ones. Your doctor will know about this. - have or had scarring on the lungs or active inflammation of the lungs (
pneumonitis ) that needs or needed treatment - have HIV, hepatitis C, an active hepatitis B infection, tuberculosis or any other active infection that needs treatment into the bloodstream. You might be able to take part if your hepatitis is controlled with medication.
- have had a stem cell transplant with somebody else’s cells (
allogeneic transplant ) or you have had anorgan transplant in the past - have inflammation of the lining of your tummy or abdomen (peritonitis) because you have developed a hole in your bowel where the cancer is
- have a blocked bowel and you haven’t had treatment
- have a problem with how your immune system works or are having treatment that damps down the immune system. This includes steroids within 7 weeks of starting trial treatment unless it was a low dose.
- have any other medical condition, mental health problem or a problem with drugs and alcohol that would affect you taking part
Other
You cannot join this trial if any of these apply. You:
- are allergic to pembrolizumab or anything it contains
- have had a live
vaccine within 30 days - are pregnant or breastfeeding
Trial design
This is a phase 2 trial. The team need 32 people to take part.
Everyone has pembrolizumab followed by surgery.
You have pembrolizumab in
You have either:
- 1 cycle of pembrolizumab if you have a low level of mutations or
- 3 cycles of pembrolizumab if you have a medium to high level of mutations
You have it as a drip into a vein. It takes about 30 minutes each time.
You then have surgery about 4 to 6 weeks after finishing pembrolizumab. Taking part in this trial means your surgery is delayed while you have pembrolizumab. This is by about 6 to 13 weeks.
Your doctor will tell you what surgery involves and how long you will stay in hospital for.
Samples for research
The researchers ask you to give some extra tissue samples. They collect these when you have a
The team also ask to take some extra blood samples. Where possible, you have these at the same time as your routine blood tests.
They plan to use the samples to:
- see how well pembrolizumab worked before surgery
- look at
genes to understand more about bowel cancer - look for substances called
biomarkers to help work out why treatment might work for some people and not for others
The team ask for 6 poo (stool) samples during the trial. They also ask you to collect 6 samples from your tongue using a swab. The team give you the sample kits to take home with you. They will give you instructions on how to collect the samples and information about how to return them.
Some of the samples are optional. You can say no to them and it won’t affect you taking part in the rest of the trial.
Quality of life
The trial team ask you to fill out a questionnaire:
- before you start treatment
- at set times during treatment
- at set times after treatment
The questionnaire asks about side effects and how you’ve been feeling. This is called a quality of life study.
Hospital visits
You see the doctor and have tests before you can take part. These include:
- a
physical examination - blood tests
- urine tests
- heart trace (ECG)
- CT scan or MRI scan
You have pembrolizumab in the day care ward. You have a check up before each dose.
You see your doctor one month after surgery for a check up. After that you see them:
- every 3 months in the first year
- about every 6 months in the second and third years
You have a CT scan or MRI scan before surgery. And then after surgery at the following timepoints:
- 6 months
- 12 months
- 24 months
- 36 months
The team ask you to have a colonoscopy at 1 year and 3 years after surgery. This is part of your routine care.
Side effects
The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.
Pembrolizumab can affect the Rarely, these side effects could be life threatening. Your doctor or nurse can explain what these side effects are, the risk of them happening and what to look out for. |
The most common side effects of pembrolizumab are:
- a drop in the number of red blood cells causing an increased risk tiredness and breathlessness (
anaemia ) - a chest infection (pneumonia)
- kidney problems
We have more information about:
Location
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Kai-Keen Shiu
Supported by
Cancer Research UK & UCL Cancer Trials Centre
Merck, Sharp & Dohme
University College London (UCL)
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040